CN103099878A - Medicament for treating acne caused by liver qi stagnation - Google Patents
Medicament for treating acne caused by liver qi stagnation Download PDFInfo
- Publication number
- CN103099878A CN103099878A CN 201310059267 CN201310059267A CN103099878A CN 103099878 A CN103099878 A CN 103099878A CN 201310059267 CN201310059267 CN 201310059267 CN 201310059267 A CN201310059267 A CN 201310059267A CN 103099878 A CN103099878 A CN 103099878A
- Authority
- CN
- China
- Prior art keywords
- stagnation
- acne
- caused
- liver
- medicament
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention relates to a medicament for treating acne caused by liver qi stagnation. The medicament comprises prunella spike, radix bupleuri, radix paeoniae alba, pericarpium citri reticulatae and honeysuckle, and has excellent effect on acne caused by liver qi stagnation.
Description
Technical field
The present invention relates to a kind of caused by hepatic stagnation qi stagnation acne treatment medicine, belong to biomedicine field.
Background technology
Acne is commonly called as comedo, be chronic inflammation pilosebaceous unit disease, be one of modal disease of department of dermatologry, its morbidity is main and sex hormone level, sebaceous gland are secreted in a large number, propionibacterium acnes propagation, the factor analysis such as the dyskeratosis of pilosebaceous duct and inflammation.Be apt to occur in hebetic masculinity and femininity, the male is slightly more than the women, but women's morbidity is early than the male.Have the teenager of 80%-90% to suffer from acne, often can naturally go down or fully recover after adolescence, individual patient also can extend to more than 30 years old.Although acne is the disease that the spontaneous recovery tendency is arranged, the untimely cicatrix that causes of acne itself and acne treatment can have a strong impact on Quality of Life, causes patient's stress and financial burden, need cause concern.Acne is apt to occur in buccal, forehead, buccal and nasolabial fold, is secondly chest, back and shoulder.
According to international improved method, acne is divided into 4 grades:
1. slight (I level): take acne as main, a small amount of papulopustule, total skin lesion is less than 30;
2. moderate (II level): acne are arranged, the pimple of moderate quatity and pustule, total skin lesion is at 30-50;
3. moderate (III level): a large amount of pimples and pustule, accidental large struvite skin lesion, widely distributed, total skin lesion number is between 51-100, and tuberosity is less than 3;
4. severe (IV level): nodositas, cyst and or the property acne, with pain and form cyst, total skin lesion is more than 100, tuberosity or cyst are more than 3.
Acne is an easily disease of recurrence, and the influence factor is a lot, and single therapy often is difficult to receive good effect, need to take Comprehensive Treatment according to the state of an illness.The common oral drugs of Acne treatment mainly contain:
1. antibiotics: oral antibiotic is one of important method of severe acne in treatment, and selecting the antibiotic for the propionibacterium acnes sensitivity is important starting point, first-selected Tetracyclines, and secondly Macrolide, reach therapeutic effect by suppressing its breeding.
2. tretinoin: oral isotretinoin is the standard treatments of the serious acne such as tuberosity cyst type, aggretion type, and its therapeutic effect is remarkable, but also have teratogenesis, blood fat raises and the side effect such as skin mucosa drying, should use under physician guidance.
3. hormones: the effect to androgen antagonist in pathogenesis of acne, reduce sebum secretion and suppress acne and generate, mainly comprise estrogen and the large class of progestogen two, as cyproterone, ethinylestradiol, diethylstilbestrol etc., also have other antagonism androgens medicines such as spironolactone, cimetidine.
4. glucocorticoid: oral glucocorticoid is mainly used in acne fulminans or acne conglobata, plays the effect of immunosuppressant and antiinflammatory.
5. Chinese patent medicine class: coptos bolus for clearing the upper heat, fangfeng tongsheng pill, danzhi xiaoyao pills, Radix Et Rhizoma Rhei Eupolyphaga seu steleophaga ball, ZHIBAI DIHUANG WAN etc.
Local external use's treatment sterilizes as main take degrease, dissolving cutin, antiinflammatory.Commonly used comprises: tretinoin preparation, benzoyl peroxide, erythromycin, chloromycetin, contain sulfur class lotion etc.
Summary of the invention
The purpose of this invention is to provide a kind of caused by hepatic stagnation qi stagnation acne treatment medicine, the weak point that exists to solve existing Drug therapy acne.
The technical solution used in the present invention is: a kind of caused by hepatic stagnation qi stagnation acne treatment medicine is characterized in that being prepared from by the crude drug of following weight portion:
Spica Prunellae 9-15 part Radix Bupleuri 3-9 part
Radix Paeoniae Alba 5-30 part Pericarpium Citri Reticulatae 3-9 part
Flos Lonicerae 6-15 part
Above-mentioned raw materials also can adopt extract, for example the commercially available extract of above-mentioned raw materials except adopting former powder.
A kind of caused by hepatic stagnation qi stagnation acne treatment medicine of the present invention, upper on the basis of mentioned component directly or again adds suitable edible or pharmaceutic adjuvant, can make capsule, tablet, granule, oral liquid, powder, teabag etc.
The above-mentioned edible or pharmaceutic adjuvant that can add comprises: diluent, suspending agent, antioxidant, emulsifying agent, disintegrating agent, adhesive and antiseptic.
Above-mentioned diluent comprises vegetable oil, molecular weight polyethylene glycol 200-6000, the third two liquor-saturated, glycerol, sorbitol, D-xylitol, calcium glycerophosphate, polyvinylpolypyrrolidone, inositol, maltose alcohol, lactobionic acid, cyclodextrin, lactose, calcium oxide, cellulose, glucose, carboxymethyl cellulose, polyvinyl butyral resin etc., and one or more in mineral oil.
Above-mentioned antioxidant comprises one or more in dibenzylatiooluene (BHT), butylated hydroxyarisol (BHA), propyl gallate, tert-butyl hydroquinone (TBHQ), malic acid, glutathion, D-xylose, glycine, a-tocopherol, a-tocopheryl acetate, sodium sulfite, inositol, ascorbic acid, phytic acid, sodium ascorbate, lecithin, hydroquinone, xylitol, succinic acid, tea polyphenols.
Above-mentioned suspending agent comprises one or more in Cera Flava, xanthan gum, arabic gum, casein, methylcellulose, Carboxymethyl cellulose sodium, carbomer, polyvinyl alcohol, hydroxyethyl-cellulose, sodium alginate, chitin, chitose, hydroxypropyl emthylcellulose, ethyl cellulose, agar, hydroxyethylmethyl-cellulose, hyprolose.
Mentioned emulsifier comprises one or more in ethylhydroxyethylcellulose, methylcellulose, glyceryl monostearate, hydroxylated lecithin, the single glycerol vinegar of acetylation, orthoformic acid, casein, ethylene glycol monostearate, diacetyl monoglyceride, acetic acid-fatty acid glycerine vinegar, Emulsifier LM-102, propylene glycol alginate.
Above-mentioned binding agent comprises methylcellulose (MC), polyvinylpyrrolidone (PVP), hydroxypropyl cellulose (HPC), hydroxypropyl emthylcellulose (HPMC), polyvinyl alcohol (PVA), Cellulose Acetate Phthalate (CAP), PVP K30, ethyl cellulose (EC), microcrystalline Cellulose (CC), acrylic resin, Semen Maydis unit, Resina persicae, maltose alcohol, poloxamer; One or more in sodium alginate, liquid glucose, Nulomoline, the acid of sucrose mono laurate.
Above-mentioned disintegrating agent comprises one or more in silica sol, Magnesiumaluminumsilicate, magnesium stearate, pregelatinized starch, cross-linking sodium carboxymethyl cellulose.
Foregoing preservatives comprises one or more in sorbic acid, Sodium Methyl Hydroxybenzoate, benzoic acid, sorbic acid methyl ester, methyl parahydroxybenzoate, P-hydroxybenzoic acid phenyl ester, butyl p-hydroxybenzoate calcium, Oleum Caryophylli, benzyl alcohol, P-hydroxybenzoic acid the third phenol sodium.
Above-mentioned capsule also comprises soft capsule except common gelatin hard-shell capsule.
The specific embodiment
The preparation of embodiment 1. capsules
9 parts of 9 parts of Radix Bupleuri of Spica Prunellae
3 parts of 30 parts of Pericarpium Citri Reticulataes of the Radix Paeoniae Alba
6 parts of Flos Loniceraes
Pulverize, cross 100 mesh sieves, encapsulated, granulate, and get final product.
The preparation of embodiment 2. oral liquids
5 parts of 12 parts of Radix Bupleuri of Spica Prunellae
6 parts of 5 parts of Pericarpium Citri Reticulataes of the Radix Paeoniae Alba
15 parts of Flos Loniceraes
Add 30 times of amounts of water, be forced into 300Mpa with hyperpressure extraction equipment, pressurize 5 minutes, extracting solution ultrafiltration, concentrated, fill, and get final product.
The preparation of embodiment 3. powders
3 parts of 15 parts of Radix Bupleuri of Spica Prunellae
9 parts of 13 parts of Pericarpium Citri Reticulataes of the Radix Paeoniae Alba
8 parts of Flos Loniceraes
Pulverize, cross 100 mesh sieves, packing, and get final product.
Claims (3)
1. caused by hepatic stagnation qi stagnation acne treatment medicine is characterized in that being prepared from by the crude drug of following weight portion:
Spica Prunellae 9-15 part Radix Bupleuri 3-9 part
Radix Paeoniae Alba 5-30 part Pericarpium Citri Reticulatae 3-9 part
Flos Lonicerae 6-15 part.
2. a kind of caused by hepatic stagnation qi stagnation acne treatment medicine as claimed in claim 1, is characterized in that also containing edible or pharmaceutic adjuvant.
3. as any one described a kind of caused by hepatic stagnation qi stagnation acne treatment medicine of claim 1-2, it is characterized in that the former powder of raw material or extract, directly or again add edible or pharmaceutic adjuvant, be prepared into capsule, tablet, granule, oral liquid, powder, teabag etc.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 201310059267 CN103099878A (en) | 2013-02-26 | 2013-02-26 | Medicament for treating acne caused by liver qi stagnation |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 201310059267 CN103099878A (en) | 2013-02-26 | 2013-02-26 | Medicament for treating acne caused by liver qi stagnation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN103099878A true CN103099878A (en) | 2013-05-15 |
Family
ID=48308290
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 201310059267 Pending CN103099878A (en) | 2013-02-26 | 2013-02-26 | Medicament for treating acne caused by liver qi stagnation |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103099878A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104587385A (en) * | 2015-01-07 | 2015-05-06 | 辛怡静 | Traditional Chinese medicine composition for treating blood stasis condensation type rosacea |
| CN113813327A (en) * | 2021-10-10 | 2021-12-21 | 陈洪旭 | Traditional Chinese medicine formula for treating liver depression and fire excess and preparation method |
-
2013
- 2013-02-26 CN CN 201310059267 patent/CN103099878A/en active Pending
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104587385A (en) * | 2015-01-07 | 2015-05-06 | 辛怡静 | Traditional Chinese medicine composition for treating blood stasis condensation type rosacea |
| CN113813327A (en) * | 2021-10-10 | 2021-12-21 | 陈洪旭 | Traditional Chinese medicine formula for treating liver depression and fire excess and preparation method |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Gupta | The efficacy of Euphorbia prostrata in early grades of symptomatic hemorrhoids–a pilot study. | |
| CN105232725A (en) | Acne removing formulation and preparing method thereof | |
| CN103083622A (en) | Compound preparation | |
| CN103099904A (en) | Traditional Chinese medicine preparation | |
| CN103417683A (en) | Health food capable of reducing blood sugar | |
| CN101804105B (en) | Medicine composition for treating mammitis and preparation method thereof | |
| CN103099878A (en) | Medicament for treating acne caused by liver qi stagnation | |
| CN103393980A (en) | Quick and effective hemostasis traditional Chinese medicine tincture | |
| CN103083580A (en) | Medical formula | |
| CN103099905A (en) | Spleen deficiency and dampness abundance type acne treatment drug | |
| CN104510853B (en) | A kind of Chinese medicinal effective-part composition for the treatment of dysmenorrhes and uses thereof | |
| CN101474192A (en) | Veramyst medicinal preparation and preparation method | |
| CN103099903A (en) | Acne therapeutic preparation | |
| CN103099931A (en) | Pharmaceutical composition | |
| CN103099930A (en) | Preparation for treating acne | |
| CN103908484A (en) | Tripterygium wilfordii plastic for treating rheumatoid arthritis and preparation method thereof | |
| CN101822781A (en) | Medicament for treating and preventing hemorrhoids | |
| CN103100062A (en) | Traditional chinese medicine composition | |
| CN103083581A (en) | Medicament for treating spleen deficiency and damp abundance acnes | |
| CN107007614A (en) | The medical usage of cycloastragenol | |
| CN104510854B (en) | A kind of Chinese medicine composition for the treatment of dysmenorrhes and uses thereof | |
| CN102935195A (en) | Traditional Chinese medicine composition for treating coronary heart disease as well as preparation method and application thereof | |
| JPH02152926A (en) | Brain edema depressant | |
| CN101428109A (en) | Medicament composition for treating piles and method of preparing the same | |
| CN106943390B (en) | Application of the Strychnos nux-vomica aglycon in preparation prevention or treatment antiarrhythmic medicament |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20130515 |